Dr. Wu Skincare Co., Ltd. (6523.TWO) develops, manufactures, and sells clinical skincare and cosmetics products primarily targeting sensitive and problem skin types in Taiwan and internationally. Founded in 2003 by dermatologist Dr. Ying-Chin Wu and his son Eric Wu and headquartered at No. 70 Section 3, Nanjing East Road, Zhongshan District, Taipei, Taiwan, the company offers hyaluronic acid moisturizing series; mandelic acid skin rejuvenating series; super anti-aging repair series; squalane plant extract repair series; translucent whitening series; laboratory essence series; super retinol rejuvenating series; capsule mask series; all-round sunscreen series; mineral flawless foundation series; beauty health food series; and readermx professional line, distributed through over 2,000 outlets including Watsons, SASA, Mannings, and e-commerce platforms such as Tmall, JD.com, Amazon, Lazada, and Shopee across Northeast Asia, Southeast Asia, and North America. The company listed on the Taipei Exchange's Emerging Stock Market in June 2016 following a minority investment from L Capital Asia, affiliated with LVMH Group, in 2014, and recently reported earnings for the second quarter and six months ended June 30, 2025, alongside the resignation of Chief Financial Officer Tina Lin effective June 30, 2025.